CILOSTAZOL

Cilostazol inhibits phosphodiesterase‑3 to increase cAMP levels, improving peripheral blood flow. Used for intermittent claudication. Side effects include headache, palpitations, and diarrhea.

SKU: 9a18634b7638 Category: Tag:

Product Description


Mechanism of Action

Cilostazol is a phosphodiesterase‑III (PDE‑3) inhibitor that increases intracellular cAMP in vascular smooth muscle and platelets. This causes vasodilation, inhibition of platelet aggregation and improved microvascular perfusion. It also modulates inflammatory pathways and endothelial nitric oxide production.

Benefits and Advantages

Used in vascular‑biology research, platelet‑activation studies, cAMP‑signalling research, peripheral‑artery‑disease modelling and PDE‑inhibitor SAR investigations.

Side Effects and Risks

Risks include tachycardia, palpitations, headache, diarrhoea, bleeding risk and contraindications in heart‑failure models. Handle with PDE‑inhibitor precautions.

Datasheet


Molecular Formula

C20H27N5O2

Molecular Weight

369.5 g/mol

CAS Number

73963-72-1

Storage Condition

Store Pletal tablets at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F).

Solubility

Practically insoluble in water

Purity

Purity information is available upon request (COA).

Synonym

cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal

IUPAC/Chemical Name

6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one

InChl Key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

InChl Code

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download